Services

Reliable and Rapid Insights into Drug Discovery

Due to cancer’s complexity, researchers are finding that a combination of drugs will be the most likely solution for a desired immune response. In order to develop effective treatments, researchers need a reliable model that allows them to analyze the drug response profile, including drug-mediated changes on tumor-infiltrating lymphocyte subpopulations and expression of immune checkpoint proteins.

Utilizing our integrated immuno-oncology platforms, Nilogen’s team of experts can provide a comprehensive analysis of drug effects on the tumor microenvironment, and interpret results in a way that informs cancer drug development.

Our platform enables you to:

• Test the immunostimulatory activity of rational combination treatments at single or multiple drug concentrations
• Test the efficacy of immune checkpoint inhibitors, both antibody-based and small molecule
• Perform ex vivo co-culture experiments with 3D tumor spheroids and matching peripheral blood mononuclear cells obtained from the same patient
• Test the pharmacodynamic activity of small molecule inhibitors
• Analyze drug effects on all components of the tumor microenvironment, including cancer-associated fibroblasts
• Test the effect of a drug on tumor cell viability [Contact us](contact) to learn more about how our platforms are facilitating research!

3D-EX℠

Nilogenʼs 3D-EX℠platform rapidly and accurately analyzes the tumor response to oncology and immuno-oncology drugs.  3D-EX℠ tumoroids are processed from fresh patient tumor tissue---without any propagation steps---for evaluation of the tumor immune microenvironment, cytotoxic efficacy of immuno-oncology drugs and tumor-drug interaction.  3D-EX℠ can also be used in the clinical setting on fresh tumor biopsy samples to guide treatment options in clinical decision-making.

• Test drug effect on tumor cell killing and T-Cell activation
• Assess the binding and efficacy of bi-specifics in solid tumors
• Analyze the immunostimulatory activity of rational combination treatments at single or multiple drug concentrations
• Perform real-time monitoring of cell viability and cell death by high-content imaging combined with multiplex cytokine analysis
• Test the efficacy of immune checkpoint inhibitors, both antibody-based and small molecule
• Analyze drug effects on all components of the tumor microenvironment, including the extra-cellular matrix
• Monitor ex vivo T-Cell trafficking and infiltration in response to immuno-modulators and anti-cancer drugs in individual patient tumors

3D - EXplore

Nilogen's new drug testing platform, 3D - EXplore, utilizes u-npropagated fresh patient tissue and combines high-content imaging with powerful multiplex cytokine analysis for accurate assessment of drug-mediated tumor cell killing and T-cell activation within the intact tumor microenvironment.

Customized options:

1. Tumor type
2. Number of treatments
3. Number of tumors
4. Read-outs include tumor cell killing and T-cell activation
5. Compare your drug against therapeutic PD1 and PD-L1 inhibitors

Further characterize the effect of your drug on the tumor microenvironment by including comprehensive gene expression analysis, flow cytometry and multiplex IHC.

Contact us today to learn more about available tumor types and how you can enroll in this innovative cost-sharing platform to achieve your drug development goals.

Click here to learn more about our 3D - EXplore technology!

Complimentary Services

Cell - Match

The Cell - Match℠ platform uses autologous patient-derived cell lines to assess, in vitro, the effect of drugs and drug combinations on the individual components of the tumor microenvironment that were isolated and propagated from each patient’s tumor.

Partner with Nilogen

Our experienced team can discuss your cancer drug development needs and assist with every step of the project, from the design and execution of the study to the preparation of the final report, including interpretation of the data.

Many pharma and biotechnology companies have trusted Nilogen for their immuno-oncology drug development, [contact us](contact) to see how we can help you.